sofosbuvir has been researched along with Coronavirus Infections in 12 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 12 (100.00) | 2.80 |
Authors | Studies |
---|---|
Elfiky, AA | 1 |
Khodarahmi, R; Sayad, B; Sobhani, M | 1 |
Khalili, H; Nourian, A | 1 |
Izzi, A; Maggi, P; Messina, V; Rinaldi, L | 1 |
Becerra, A; Campillo-Balderas, JA; Jácome, R; Lazcano, A; Ponce de León, S | 1 |
Anderson, TK; Chien, M; Jockusch, S; Ju, J; Kirchdoerfer, RN; Kumar, S; Li, X; Russo, JJ; Tao, C | 1 |
Abbaspour Kasgari, H; Alikhani, A; Babamahmoodi, F; Davoudi Badabi, AR; Davoudi, L; Garratt, A; Hedayatizadeh Omran, A; Hill, A; Levi, J; Merat, S; Moradi, S; Saeedi, M; Shabani, AM; Simmons, B; Tirgar Fakheri, H; Wentzel, H | 1 |
Afhami, S; Akbarpour, E; Ali Asgari, A; Aliannejad, R; Anushirvani, A; Davarpanah, AH; Garratt, A; Hill, A; Hosamirudsai, H; Kheiri, Z; Levi, J; Merat, S; Montazeri, M; Norouzi, A; Qavi, A; Radmard, AR; Sadeghi, A; Simmons, B; Wentzel, H | 1 |
Bitaraf, S; Eslami, G; Esmaeilian, H; Freeman, J; Hajizadeh Farsani, M; Hill, A; Jafari Kashi, AH; Jelvay, S; Lotfi, Z; Marjani, S; Mobarak, M; Mobarak, S; Momtazan, M; Mousaviasl, S; Radmanesh, E; Sadeghi, A; Salmanzadeh, S; Simmons, B; Tabibi, R; Talebzadeh, SM; Wentzel, H; Wickramatillake, A | 1 |
Perišić, O | 1 |
Chien, M; Jockusch, S; Ju, J; Kalachikov, S; Kumar, S; Li, X; Morozova, I; Russo, JJ; Tao, C | 1 |
Chien, M; Jockusch, S; Ju, J; Kalachikov, S; Kirchdoerfer, RN; Kumar, S; Li, X; Morozova, I; Russo, JJ; Tao, C | 1 |
3 trial(s) available for sofosbuvir and Coronavirus Infections
Article | Year |
---|---|
Evaluation of the efficacy of sofosbuvir plus daclatasvir in combination with ribavirin for hospitalized COVID-19 patients with moderate disease compared with standard care: a single-centre, randomized controlled trial.
Topics: Adult; Aged; Antiviral Agents; Betacoronavirus; Carbamates; Coronavirus Infections; COVID-19; Drug Therapy, Combination; Female; Hospitalization; Humans; Imidazoles; Iran; Male; Middle Aged; Pandemics; Pneumonia, Viral; Pyrrolidines; Ribavirin; SARS-CoV-2; Sofosbuvir; Treatment Outcome; Valine | 2020 |
Sofosbuvir and daclatasvir compared with standard of care in the treatment of patients admitted to hospital with moderate or severe coronavirus infection (COVID-19): a randomized controlled trial.
Topics: Adult; Aged; Antiviral Agents; Betacoronavirus; Carbamates; Coronavirus Infections; COVID-19; Drug Therapy, Combination; Female; Humans; Imidazoles; Iran; Male; Middle Aged; Pandemics; Patient Admission; Pneumonia, Viral; Pyrrolidines; SARS-CoV-2; Severity of Illness Index; Sofosbuvir; Treatment Outcome; Valine | 2020 |
The impact of sofosbuvir/daclatasvir or ribavirin in patients with severe COVID-19.
Topics: Adult; Aged; Antiviral Agents; Betacoronavirus; Carbamates; Coronavirus Infections; COVID-19; Drug Therapy, Combination; Female; Humans; Imidazoles; Male; Middle Aged; Pandemics; Pneumonia, Viral; Pyrrolidines; Ribavirin; SARS-CoV-2; Sofosbuvir; Treatment Outcome; Valine | 2020 |
9 other study(ies) available for sofosbuvir and Coronavirus Infections
Article | Year |
---|---|
Anti-HCV, nucleotide inhibitors, repurposing against COVID-19.
Topics: Adenosine Monophosphate; Alanine; Alphacoronavirus; Amino Acid Sequence; Antiviral Agents; Betacoronavirus; Catalytic Domain; Computational Biology; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Drug Repositioning; Guanosine Monophosphate; Guanosine Triphosphate; Humans; Molecular Docking Simulation; Pneumonia, Viral; Protein Binding; Protein Conformation, alpha-Helical; Protein Conformation, beta-Strand; Protein Interaction Domains and Motifs; Ribavirin; RNA-Dependent RNA Polymerase; SARS-CoV-2; Sequence Alignment; Sequence Homology, Amino Acid; Sofosbuvir; Thermodynamics; Uridine Triphosphate; Viral Proteins | 2020 |
Sofosbuvir as Repurposed Antiviral Drug Against COVID-19: Why Were We Convinced to Evaluate the Drug in a Registered/Approved Clinical Trial?
Topics: Antiviral Agents; Betacoronavirus; Carbamates; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Drug Repositioning; Heterocyclic Compounds, 4 or More Rings; Humans; Iran; Pandemics; Patient Safety; Pneumonia, Viral; SARS-CoV-2; Sofosbuvir | 2020 |
Sofosbuvir as a potential option for the treatment of COVID-19.
Topics: Antiviral Agents; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Humans; Pandemics; Pneumonia, Viral; SARS-CoV-2; Sofosbuvir | 2020 |
Editorial - Sofosbuvir/Velpatasvir as a combination with strong potential activity against SARS-CoV2 (COVID-19) infection: how to use direct-acting antivirals as broad-spectrum antiviral agents.
Topics: Antiviral Agents; Betacoronavirus; Carbamates; Coronavirus Infections; COVID-19; DNA-Directed DNA Polymerase; Drug Therapy, Combination; Heterocyclic Compounds, 4 or More Rings; Humans; Pandemics; Pneumonia, Viral; SARS-CoV-2; Sofosbuvir; Viral Proteins | 2020 |
Sofosbuvir as a potential alternative to treat the SARS-CoV-2 epidemic.
Topics: Antiviral Agents; Base Sequence; Betacoronavirus; Catalytic Domain; Computer Simulation; Coronavirus Infections; Coronavirus RNA-Dependent RNA Polymerase; COVID-19; Humans; Middle East Respiratory Syndrome Coronavirus; Pandemics; Pneumonia, Viral; Protein Binding; Protein Structure, Tertiary; RNA-Dependent RNA Polymerase; SARS-CoV-2; Severe Acute Respiratory Syndrome; Severe acute respiratory syndrome-related coronavirus; Sofosbuvir; Viral Nonstructural Proteins | 2020 |
Nucleotide Analogues as Inhibitors of SARS-CoV-2 Polymerase, a Key Drug Target for COVID-19.
Topics: Antiviral Agents; Betacoronavirus; Coronavirus Infections; COVID-19; Dideoxynucleosides; Humans; Pandemics; Pneumonia, Viral; RNA-Dependent RNA Polymerase; SARS-CoV-2; Sofosbuvir; Viral Nonstructural Proteins | 2020 |
Recognition of Potential COVID-19 Drug Treatments through the Study of Existing Protein-Drug and Protein-Protein Structures: An Analysis of Kinetically Active Residues.
Topics: Adenosine Monophosphate; Alanine; Angiotensin-Converting Enzyme 2; Antibodies, Viral; Antigen-Antibody Reactions; Antiviral Agents; Betacoronavirus; Binding Sites; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Drug Repositioning; Eflornithine; Humans; Hydrophobic and Hydrophilic Interactions; Ivermectin; L-Lactate Dehydrogenase; Models, Molecular; Molecular Docking Simulation; Pandemics; Peptidyl-Dipeptidase A; Pneumonia, Viral; Proline; Protein Binding; Protein Conformation; Protein Interaction Mapping; Receptors, Glycine; Saposins; SARS-CoV-2; Sofosbuvir; Spike Glycoprotein, Coronavirus; Structure-Activity Relationship | 2020 |
Sofosbuvir terminated RNA is more resistant to SARS-CoV-2 proofreader than RNA terminated by Remdesivir.
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Betacoronavirus; Coronavirus Infections; Coronavirus RNA-Dependent RNA Polymerase; COVID-19; Drug Discovery; Drug Repositioning; Exonucleases; Hepacivirus; Hepatitis C; Humans; Pandemics; Pneumonia, Viral; Prodrugs; RNA-Dependent RNA Polymerase; RNA, Viral; SARS-CoV-2; Sofosbuvir; Viral Nonstructural Proteins; Virus Replication | 2020 |
Nucleotide analogues as inhibitors of SARS-CoV Polymerase.
Topics: Antiviral Agents; Betacoronavirus; Carbamates; Coronavirus Infections; COVID-19; Dideoxynucleotides; Drug Combinations; Heterocyclic Compounds, 4 or More Rings; Humans; Pandemics; Pneumonia, Viral; RNA-Dependent RNA Polymerase; SARS-CoV-2; Sofosbuvir; Thymine Nucleotides; Zidovudine | 2020 |